Paper Details

  1. Home
  2. Paper Details

Etanercept for the treatment of rheumatoid arthritis.

Author: BlumenauerB, BurlsA, CoyleD, CranneyA, HochbergM, JuddM, TugwellP, WellsG

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Etanercept 25 mg SC twice weekly was more efficacious than control treatment for ACR 20, 50 and 70 at 6 months, and over 12 months it slowed joint damage.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Etanercept is a soluble tumour necrosis factor alpha-receptor DMARD for the treatment of rheumatoid arthritis (RA). OBJECTIVES: To assess the efficacy and safety of etanercept for the treatment of RA. SEARCH STRATEGY: Five electronic databases were searched from 1966 to February 2003 w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD004525

データ提供：米国国立医学図書館（NLM）

Etanercept for the Treatment of Rheumatoid Arthritis

This research investigates the efficacy and safety of etanercept, a soluble tumor necrosis factor alpha-receptor drug, for the treatment of rheumatoid arthritis (RA). The study, a [systematic review] of [three randomized controlled trials], evaluated the effectiveness of etanercept in reducing RA symptoms and slowing joint damage. The authors found that etanercept, particularly at a dose of [25 mg subcutaneously twice weekly], was significantly more effective than control treatment in improving RA symptoms and reducing joint damage. The review also highlighted the acceptable withdrawal and toxicity rates associated with etanercept.

Etanercept Shows Promise in Rheumatoid Arthritis Treatment

The study's findings suggest that etanercept could be a valuable treatment option for RA patients, offering significant improvements in symptoms and slowing the progression of joint damage. The drug's effectiveness in reducing RA symptoms was notable, with a [64%] response rate for ACR 20, a [39%] response rate for ACR 50, and a [15%] response rate for ACR 70. These findings suggest that etanercept could provide substantial relief for RA patients, helping them navigate the challenging journey of living with this chronic disease.

Navigating the Landscape of Rheumatoid Arthritis Treatment

This research sheds light on the promising role of etanercept in RA treatment. The study's findings offer hope for RA patients seeking effective ways to manage their condition and improve their quality of life. It's like discovering a new path through a desert, offering a smoother and more navigable route for those facing the challenges of RA.

Dr. Camel's Conclusion

This review highlights etanercept's potential as a valuable treatment option for RA patients. The study's findings demonstrate its efficacy in reducing symptoms and slowing joint damage, offering hope for those seeking relief from this debilitating disease. It's like finding a refreshing oasis in the desert, providing a much-needed respite and a path toward improved well-being for those affected by RA.

Date :
  1. Date Completed 2004-05-04
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

14584021

DOI: Digital Object Identifier

10.1002/14651858.CD004525

Related Literature

Article Analysis
・Effective treatment of rheumatoid arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.